Medical device manufacturer Medtronic has received approval from the Food and Drug Administration for the Altaviva system, a straightforward device aimed at managing urge urinary incontinence.
Medtronic, the leading global healthcare technology company headquartered in Galway, Ireland, has made a significant stride in the field of bladder control treatments. The company has received FDA approval for the Altaviva™ device, an implantable tibial neuromodulation therapy designed to treat urge urinary incontinence, a common symptom of overactive bladder (OAB).
The Altaviva device is a testament to Medtronic's 30-year commitment to improving the lives of people with bladder control symptoms. This innovative device, once inserted near the ankle during a minimally invasive procedure that doesn't require sedation or imaging, delivers therapy automatically, requiring no daily intervention or manual adjustments from the patient.
The device is activated upon the patient's return home and boasts a remarkable 15-year battery lifespan under expected therapy settings. It is rechargeable, with a recharging time of up to 30 minutes when using the default recharging speed. The Altaviva device is also MRI-compatible, providing patients with peace of mind for planned or unexpected medical imaging.
The Altaviva device sends electrical impulses to the tibial nerve, helping restore communication between the bladder and the brain to regulate bladder control. This technology is a significant step forward in the treatment landscape for urge urinary incontinence, a condition that affects millions of people worldwide.
Medtronic plc employs over 95,000 people across more than 150 countries and offers a diverse product portfolio including cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. For more information about Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.
For media inquiries, please contact Laurel Hood at 763-514-0249. For investor relations, please contact Ryan Weispfenning at 1-763-505-4626.
Medtronic's mission is to alleviate pain, restore health, and extend life. With the introduction of the Altaviva device, the company continues to fulfil this mission, offering hope and relief to those affected by urge urinary incontinence. On October 9, 2025, Medtronic will host an investor call to discuss the Altaviva device and its impact on the treatment landscape for urge urinary incontinence.
The Altaviva device is just one example of Medtronic's technologies and therapies that treat 70 health conditions. As a pioneer in healthcare technology, Medtronic continues to push the boundaries of innovation, improving the quality of life for millions of people worldwide.
Read also:
- Overweight women undergoing IVF have a 47% higher chance of conceiving naturally post-weight loss
- Bonsai Trees from Evergreen Species: Exploring Growth Characteristics & Distinct Qualities
- What temperatures may make walking your canine companion uncomfortable?
- Title: Information About Beovu: Potency, Form, Usage, and Additional Details
